{
    "info": {
        "nct_id": "NCT05200559",
        "official_title": "The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study",
        "inclusion_criteria": "* Ability to comply with the study protocol, in the investigator's judgment\n* Histologically or cytologically confirmed solid tumors (cutaneous melanoma, non-small cell lung cancer, renal cell carcinoma, endometrial cancer, ovarian cancer, MSI-H solid tumors (deficient mismatch repair system or other solid tumors) that have progressed on or refractory to standard of care therapies for their disease\n* Phase I dose escalation phase\n\n  * Advanced metastatic or recurrent solid tumors (where pembrolizumab is approved and/or have shown efficacy) that have progressed on or refractory to standard of care therapies for their disease\n  * Prior anti-PD1 or PDL1 therapy is allowed\n  * Prior anti-CTLA4 therapy is allowed if had anti-CTLA4 free interval of 6 months or more\n  * At least one prior line of therapy in the dose escalation phase\n* Phase Ib dose expansion cohorts\n\n  * Platinum-resistant recurrent ovarian cancer (recurred within 6 months or less of prior platinum therapy) or post-PD1/PDL1 MSI-H cancers (mismatch repair deficient tumors). Patients in the ovarian cancer cohort must have received chemotherapy plus bevacizumab unless bevacizumab is contra-indicated or considered risky per treating physician.\n  * Prior 1-5 lines of therapy for dose expansion\n  * Prior anti-PD1/PDL1 therapy is allowed in the MSI-H cohort but not in the ovarian cohort\n  * Prior anti-CTLA4 therapy is not allowed.\n  * Primary platinum- refractory cancers are excluded in the dose expansion (progressed during or within 3 months of primary platinum therapy)\n* Measurable disease per RECIST v1.1\n\n  o Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.\n* Availability of a representative tumor specimen for exploratory biomarker research\n* ECOG Performance Status of 0-1\n* Life expectancy ≥ 6 months\n* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:\n\n  * ANC ≥ 1.5 × 109/L (1500/L) without granulocyte colony-stimulating factor support\n  * Platelet count ≥ 100 × 109/L (100,000/L) without transfusion\n  * Hemoglobin ≥ 90 g/L (9 g/dL) o Patients may be transfused to meet this criterion.\n  * AST, ALT, and alkaline phosphatase (ALP) ≤2.5 × upper limit of normal (ULN), with the following exceptions:\n\n    * Patients with documented liver metastases: AST and ALT ≤ 5 × ULN\n    * Patients with documented liver or bone metastases: ALP ≤ 5 × ULN\n  * Serum bilirubin ≤1.5 × ULN with the following exception:\n\n    o Patients with known Gilbert disease: serum bilirubin ≤3 × ULN\n  * Serum creatinine ≤1.5 × ULN}\n  * Serum albumin ≥ 25 g/L (2.5 g/dL)\n  * For patients not receiving therapeutic anticoagulation: INR or aPTT × 1.5 × ULN o For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Patients with a positive HIV disease are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ≥ 200/μL, and have an undetectable viral load\n* No known Hepatitis infection\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:\n\n  * Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of pembrolizumab and E7777. Women must refrain from donating eggs during this same period.\n  * A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:\n\n  * With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after the final dose of pembrolizumab + E7777 to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n  * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Patients who meet any of the following criteria will be excluded from study entry:\n\n  * History of leptomeningeal disease. Patients with brain metastasis are allowed if their brain metastasis was adequately treated with surgery or radiation or both, have been stable for at least 6 months and not on steroids.\n  * Uncontrolled tumor-related pain\n\n    * Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.\n    * Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment.\n  * Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n\n    o Patients with indwelling catheters (e.g., PleurX™) are allowed.\n  * Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)\n  * Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:\n\n    * Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.\n    * Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.\n    * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n      * Rash must cover < 10% of body surface area\n      * Disease is well controlled at baseline and requires only low-potency topical corticosteroids\n      * No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months\n  * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan\n\n    o History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n  * Active tuberculosis\n  * Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina\n  * Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n  * History of concurrent second primary malignancy other than the primary cancer within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer\n  * Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n  * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n\n    o Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n  * Prior allogeneic stem cell or solid organ transplantation\n  * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n  * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during pembrolizumab treatment or within 5 months after the final dose of pembrolizumab\n  * Has a known history of human immunodeficiency virus (HIV) infection or HIV test (+) in screening test. No HIV testing is required unless mandated by local health authority. Patients with HIV infection with following exception are allowed: HIV-infected patients on effective anti-retroviral therapy with viral load within 6 months of enrollment are eligible for this trial.\n  * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection except following situation: Patients with a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection are allowed to be included if: participant on a stable dose of antiviral therapy, HBV viral load below the limit of quantification. HCV viral load below the limit of quantification.\n  * Treatment with investigational therapy within 28 days prior to initiation of study treatment\n  * Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies except what is specified in the inclusion criteria.\n\n    o Prior anti-PD1 or anti-CTLA4 therapy is allowed in the dose escalation cohort and prior PD1/PDL1 inhibitors are allowed in the MSI-H expansion cohort.\n  * Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment\n  * Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:\n\n    * Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.\n    * Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.\n  * History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins\n  * Known hypersensitivity to Chinese hamster ovary cell products or to any component of the pembrolizumab formulation\n  * Known allergy or hypersensitivity to any component of the E7777 formulation\n  * Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months for pembrolizumab and E7777 after the final dose of study treatment o Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.",
            "criterions": [
                {
                    "exact_snippets": "postmenarchal",
                    "criterion": "menarche status",
                    "requirements": [
                        {
                            "requirement_type": "postmenarchal",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause)",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "has not undergone surgical sterilization (removal of ovaries and/or uterus)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "surgically sterilized",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤1.5 × ULN}",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤1.5 × ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.",
            "criterions": [
                {
                    "exact_snippets": "The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "reliability",
                            "expected_value": "reliable in relation to trial duration and patient's lifestyle"
                        }
                    ]
                },
                {
                    "exact_snippets": "Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "periodic abstinence or withdrawal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one prior line of therapy in the dose escalation phase",
            "criterions": [
                {
                    "exact_snippets": "At least one prior line of therapy in the dose escalation phase",
                    "criterion": "prior lines of therapy in the dose escalation phase",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-CTLA4 therapy is allowed if had anti-CTLA4 free interval of 6 months or more",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-CTLA4 therapy is allowed if had anti-CTLA4 free interval of 6 months or more",
                    "criterion": "prior anti-CTLA4 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "free interval since last anti-CTLA4 therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin ≤1.5 × ULN with the following exception:",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin ≤1.5 × ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "o Patients with known Gilbert disease: serum bilirubin ≤3 × ULN",
            "criterions": [
                {
                    "exact_snippets": "Patients with known Gilbert disease",
                    "criterion": "Gilbert disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serum bilirubin ≤3 × ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:",
            "criterions": [
                {
                    "exact_snippets": "For men: agreement to remain abstinent (refrain from heterosexual intercourse)",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual intercourse",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For men: ... or use a condom",
                    "criterion": "condom use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to refrain from donating sperm",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Primary platinum- refractory cancers are excluded in the dose expansion (progressed during or within 3 months of primary platinum therapy)",
            "criterions": [
                {
                    "exact_snippets": "Primary platinum- refractory cancers are excluded",
                    "criterion": "primary platinum-refractory cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "progressed during or within 3 months of primary platinum therapy",
                    "criterion": "progression during or within 3 months of primary platinum therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression_timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a positive HIV disease are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ≥ 200/μL, and have an undetectable viral load",
            "criterions": [
                {
                    "exact_snippets": "positive HIV disease",
                    "criterion": "HIV disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "stable on anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CD4 count ≥ 200/μL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-PD1/PDL1 therapy is allowed in the MSI-H cohort but not in the ovarian cohort",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-PD1/PDL1 therapy is allowed in the MSI-H cohort",
                    "criterion": "prior anti-PD1/PDL1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "MSI-H"
                        }
                    ]
                },
                {
                    "exact_snippets": "not in the ovarian cohort",
                    "criterion": "prior anti-PD1/PDL1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "ovarian"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to comply with the study protocol, in the investigator's judgment",
            "criterions": [
                {
                    "exact_snippets": "Ability to comply with the study protocol, in the investigator's judgment",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 90 g/L (9 g/dL) o Patients may be transfused to meet this criterion.",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 90 g/L (9 g/dL)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients may be transfused to meet this criterion",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "method of achieving value",
                            "expected_value": "transfusion allowed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-PD1 or PDL1 therapy is allowed",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-PD1 or PDL1 therapy is allowed",
                    "criterion": "prior anti-PD1 or PDL1 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST, ALT, and alkaline phosphatase (ALP) ≤2.5 × upper limit of normal (ULN), with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "AST ... ≤2.5 × upper limit of normal (ULN)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ... ≤2.5 × upper limit of normal (ULN)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alkaline phosphatase (ALP) ≤2.5 × upper limit of normal (ULN)",
                    "criterion": "alkaline phosphatase (ALP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after the final dose of pembrolizumab + E7777 to avoid exposing the embryo. Men must refrain from donating sperm during this same period.",
            "criterions": [
                {
                    "exact_snippets": "With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after the final dose of pembrolizumab + E7777 to avoid exposing the embryo.",
                    "criterion": "sexual activity with female partner of childbearing potential or pregnant female partner",
                    "requirements": [
                        {
                            "requirement_type": "contraception/abstinence",
                            "expected_value": [
                                "abstinence",
                                "condom use"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "treatment period"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months after final dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Men must refrain from donating sperm during this same period.",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "treatment period"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "months after final dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Advanced metastatic or recurrent solid tumors (where pembrolizumab is approved and/or have shown efficacy) that have progressed on or refractory to standard of care therapies for their disease",
            "criterions": [
                {
                    "exact_snippets": "Advanced metastatic or recurrent solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "where pembrolizumab is approved and/or have shown efficacy",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "pembrolizumab efficacy or approval",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that have progressed on or refractory to standard of care therapies for their disease",
                    "criterion": "response to standard of care therapies",
                    "requirements": [
                        {
                            "requirement_type": "progression or refractory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG Performance Status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin ≥ 25 g/L (2.5 g/dL)",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin ≥ 25 g/L (2.5 g/dL)",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platinum-resistant recurrent ovarian cancer (recurred within 6 months or less of prior platinum therapy) or post-PD1/PDL1 MSI-H cancers (mismatch repair deficient tumors). Patients in the ovarian cancer cohort must have received chemotherapy plus bevacizumab unless bevacizumab is contra-indicated or considered risky per treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Platinum-resistant recurrent ovarian cancer (recurred within 6 months or less of prior platinum therapy)",
                    "criterion": "ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "platinum-resistance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recurrence_interval_after_platinum_therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "post-PD1/PDL1 MSI-H cancers (mismatch repair deficient tumors)",
                    "criterion": "MSI-H cancer",
                    "requirements": [
                        {
                            "requirement_type": "post_PD1/PDL1_therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "mismatch_repair_deficiency",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients in the ovarian cancer cohort must have received chemotherapy plus bevacizumab unless bevacizumab is contra-indicated or considered risky per treating physician.",
                    "criterion": "chemotherapy plus bevacizumab treatment in ovarian cancer cohort",
                    "requirements": [
                        {
                            "requirement_type": "chemotherapy_received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "bevacizumab_received",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "bevacizumab_exception",
                            "expected_value": [
                                "contra-indicated",
                                "considered risky per treating physician"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "o Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.",
            "criterions": [
                {
                    "exact_snippets": "Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.",
                    "criterion": "previously irradiated lesions",
                    "requirements": [
                        {
                            "requirement_type": "measurable disease eligibility",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "boolean (eligible)"
                            }
                        },
                        {
                            "requirement_type": "progressive disease documentation since radiation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of pembrolizumab and E7777. Women must refrain from donating eggs during this same period.",
            "criterions": [
                {
                    "exact_snippets": "Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of pembrolizumab and E7777.",
                    "criterion": "contraception during and after treatment",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive method failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for 5 months after the final dose of pembrolizumab and E7777"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women must remain abstinent ... during the treatment period and for 5 months after the final dose of pembrolizumab and E7777.",
                    "criterion": "sexual abstinence during and after treatment",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for 5 months after the final dose of pembrolizumab and E7777"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women must refrain from donating eggs during this same period.",
                    "criterion": "egg donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating eggs",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for 5 months after the final dose of pembrolizumab and E7777"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase Ib dose expansion cohorts",
            "criterions": [
                {
                    "exact_snippets": "Phase Ib dose expansion cohorts",
                    "criterion": "trial phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "Ib"
                        }
                    ]
                },
                {
                    "exact_snippets": "dose expansion cohorts",
                    "criterion": "cohort type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "dose expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients not receiving therapeutic anticoagulation: INR or aPTT × 1.5 × ULN o For patients receiving therapeutic anticoagulation: stable anticoagulant regimen",
            "criterions": [
                {
                    "exact_snippets": "For patients not receiving therapeutic anticoagulation: INR or aPTT × 1.5 × ULN",
                    "criterion": "INR or aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients receiving therapeutic anticoagulation: stable anticoagulant regimen",
                    "criterion": "anticoagulant regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior 1-5 lines of therapy for dose expansion",
            "criterions": [
                {
                    "exact_snippets": "Prior 1-5 lines of therapy for dose expansion",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-CTLA4 therapy is not allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-CTLA4 therapy is not allowed.",
                    "criterion": "prior anti-CTLA4 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase I dose escalation phase",
            "criterions": [
                {
                    "exact_snippets": "Phase I dose escalation phase",
                    "criterion": "trial phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "I"
                        }
                    ]
                },
                {
                    "exact_snippets": "dose escalation phase",
                    "criterion": "dose escalation",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST v1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST v1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with documented liver or bone metastases: ALP ≤ 5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "documented liver or bone metastases",
                    "criterion": "liver or bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ALP ≤ 5 × ULN",
                    "criterion": "alkaline phosphatase (ALP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with documented liver metastases: AST and ALT ≤ 5 × ULN",
            "criterions": [
                {
                    "exact_snippets": "documented liver metastases",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT ≤ 5 × ULN",
                    "criterion": "AST and ALT levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed solid tumors (cutaneous melanoma, non-small cell lung cancer, renal cell carcinoma, endometrial cancer, ovarian cancer, MSI-H solid tumors (deficient mismatch repair system or other solid tumors) that have progressed on or refractory to standard of care therapies for their disease",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed solid tumors",
                    "criterion": "solid tumor diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cutaneous melanoma, non-small cell lung cancer, renal cell carcinoma, endometrial cancer, ovarian cancer, MSI-H solid tumors (deficient mismatch repair system or other solid tumors)",
                    "criterion": "tumor type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "cutaneous melanoma",
                                "non-small cell lung cancer",
                                "renal cell carcinoma",
                                "endometrial cancer",
                                "ovarian cancer",
                                "MSI-H solid tumors",
                                "deficient mismatch repair system solid tumors",
                                "other solid tumors"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "that have progressed on or refractory to standard of care therapies for their disease",
                    "criterion": "response to standard of care therapies",
                    "requirements": [
                        {
                            "requirement_type": "disease status after standard of care",
                            "expected_value": [
                                "progressed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure",
            "criterions": [
                {
                    "exact_snippets": "The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "reliability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "in relation to the duration of the clinical trial"
                        },
                        {
                            "requirement_type": "lifestyle compatibility",
                            "expected_value": "in relation to the preferred and usual lifestyle of the patient"
                        }
                    ]
                },
                {
                    "exact_snippets": "Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure",
                    "criterion": "contraceptive method",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "periodic abstinence or withdrawal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of a representative tumor specimen for exploratory biomarker research",
            "criterions": [
                {
                    "exact_snippets": "Availability of a representative tumor specimen",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "representativeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for exploratory biomarker research",
                    "criterion": "tumor specimen suitability for exploratory biomarker research",
                    "requirements": [
                        {
                            "requirement_type": "suitability for exploratory biomarker research",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No known Hepatitis infection",
            "criterions": [
                {
                    "exact_snippets": "No known Hepatitis infection",
                    "criterion": "Hepatitis infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:",
            "criterions": [
                {
                    "exact_snippets": "For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse)",
                    "criterion": "sexual activity",
                    "requirements": [
                        {
                            "requirement_type": "abstinence from heterosexual intercourse",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For women of childbearing potential: ... or use contraceptive methods",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "use of contraceptive methods",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For women of childbearing potential: ... agreement to refrain from donating eggs",
                    "criterion": "egg donation",
                    "requirements": [
                        {
                            "requirement_type": "refrain from donating eggs",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic ... function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... end-organ function",
                    "criterion": "end-organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory test results, obtained within 14 days prior to initiation of study treatment",
                    "criterion": "laboratory test timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before study treatment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Uncontrolled tumor-related pain",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled tumor-related pain",
                    "criterion": "tumor-related pain",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy or hypersensitivity to any component of the E7777 formulation",
            "criterions": [
                {
                    "exact_snippets": "Known allergy or hypersensitivity to any component of the E7777 formulation",
                    "criterion": "allergy or hypersensitivity to any component of the E7777 formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced pneumonitis",
                    "criterion": "drug-induced pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pneumonitis",
                    "criterion": "idiopathic pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_CT_scan",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Rash must cover < 10% of body surface area",
            "criterions": [
                {
                    "exact_snippets": "Rash must cover < 10% of body surface area",
                    "criterion": "rash",
                    "requirements": [
                        {
                            "requirement_type": "body surface area coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... ascites requiring recurrent drainage procedures (once monthly or more frequently)",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "drainage frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.",
            "criterions": [
                {
                    "exact_snippets": "Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.",
                    "criterion": "receipt of acute, low-dose or one-time pulse dose systemic immunosuppressant medication",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "acute, low-dose systemic immunosuppressant medication",
                                "one-time pulse dose of systemic immunosuppressant medication"
                            ]
                        },
                        {
                            "requirement_type": "principal investigator confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months",
            "criterions": [
                {
                    "exact_snippets": "No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months",
                    "criterion": "acute exacerbations of the underlying condition requiring specified therapies",
                    "requirements": [
                        {
                            "requirement_type": "occurrence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "therapies",
                            "expected_value": [
                                "psoralen plus ultraviolet A radiation",
                                "methotrexate",
                                "retinoids",
                                "biologic agents",
                                "oral calcineurin inhibitors",
                                "high-potency or oral corticosteroids"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "o Patients with indwelling catheters (e.g., PleurX™) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Patients with indwelling catheters (e.g., PleurX™) are allowed.",
                    "criterion": "indwelling catheters",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment",
                    "criterion": "treatment with systemic immunostimulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with investigational therapy within 28 days prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with investigational therapy within 28 days prior to initiation of study treatment",
                    "criterion": "treatment with investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies except what is specified in the inclusion criteria.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with CD137 agonists",
                    "criterion": "prior treatment with CD137 agonists",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
                    "criterion": "prior treatment with immune checkpoint blockade therapies",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy types",
                            "expected_value": [
                                "anti-CTLA-4 therapeutic antibodies",
                                "anti-PD-1 therapeutic antibodies",
                                "anti-PD-L1 therapeutic antibodies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known history of human immunodeficiency virus (HIV) infection or HIV test (+) in screening test. No HIV testing is required unless mandated by local health authority. Patients with HIV infection with following exception are allowed: HIV-infected patients on effective anti-retroviral therapy with viral load within 6 months of enrollment are eligible for this trial.",
            "criterions": [
                {
                    "exact_snippets": "Has a known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "history of HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV test (+) in screening test",
                    "criterion": "HIV test result at screening",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV-infected patients on effective anti-retroviral therapy with viral load within 6 months of enrollment are eligible",
                    "criterion": "HIV-infected patients on effective anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "anti-retroviral therapy effectiveness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load measurement recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell or solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell ... transplantation",
                    "criterion": "allogeneic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disease is well controlled at baseline and requires only low-potency topical corticosteroids",
            "criterions": [
                {
                    "exact_snippets": "Disease is well controlled at baseline",
                    "criterion": "disease control status at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires only low-potency topical corticosteroids",
                    "criterion": "corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low-potency"
                        },
                        {
                            "requirement_type": "route of administration",
                            "expected_value": "topical"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with controlled Type 1 diabetes mellitus",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "who are on an insulin regimen",
                    "criterion": "insulin regimen",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (e.g., epidural metastasis that is not currently associated with spinal cord compression) should be considered for loco-regional therapy if appropriate prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Asymptomatic metastatic lesions",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic lesions that would likely cause functional deficits or intractable pain with further growth",
                    "criterion": "metastatic lesions",
                    "requirements": [
                        {
                            "requirement_type": "risk of functional deficits with further growth",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "risk of intractable pain with further growth",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "epidural metastasis that is not currently associated with spinal cord compression",
                    "criterion": "epidural metastasis",
                    "requirements": [
                        {
                            "requirement_type": "spinal cord compression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients who received mineralocorticoids (e.g., fludrocortisone) ... are eligible for the study.",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma ... are eligible for the study.",
                    "criterion": "corticosteroid use for COPD or asthma",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency ... are eligible for the study.",
                    "criterion": "low-dose corticosteroid use for orthostatic hypotension or adrenal insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "history of use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during pembrolizumab treatment or within 5 months after the final dose of pembrolizumab",
            "criterions": [
                {
                    "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment",
                    "criterion": "treatment with live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for such a vaccine during pembrolizumab treatment or within 5 months after the final dose of pembrolizumab",
                    "criterion": "anticipated need for live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "anticipated timing",
                            "expected_value": [
                                "during pembrolizumab treatment",
                                "within 5 months after the final dose of pembrolizumab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 6 months for pembrolizumab and E7777 after the final dose of study treatment o Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy or breastfeeding",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnancy or breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intention of becoming pregnant during study treatment or within 6 months for pembrolizumab and E7777 after the final dose of study treatment",
                    "criterion": "intention to become pregnant",
                    "requirements": [
                        {
                            "requirement_type": "timeframe",
                            "expected_value": [
                                "during study treatment",
                                "within 6 months for pembrolizumab and E7777 after the final dose of study treatment"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment",
                    "criterion": "serum pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 14 days prior to initiation of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "childbearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "o Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.",
                    "criterion": "prophylactic antibiotic use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of leptomeningeal disease. Patients with brain metastasis are allowed if their brain metastasis was adequately treated with surgery or radiation or both, have been stable for at least 6 months and not on steroids.",
            "criterions": [
                {
                    "exact_snippets": "History of leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastasis are allowed if their brain metastasis was adequately treated with surgery or radiation or both",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "surgery",
                                "radiation",
                                "surgery and radiation"
                            ]
                        },
                        {
                            "requirement_type": "treatment adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have been stable for at least 6 months",
                    "criterion": "brain metastasis stability",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not on steroids",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only",
                    "criterion": "history of eczema, psoriasis, lichen simplex chronicus, or vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with psoriatic arthritis are excluded",
                    "criterion": "psoriatic arthritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "o History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
            "criterions": [
                {
                    "exact_snippets": "History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
                    "criterion": "history of radiation pneumonitis in the radiation field (fibrosis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the pembrolizumab formulation",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity ... to any component of the pembrolizumab formulation",
                    "criterion": "hypersensitivity to any component of the pembrolizumab formulation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune-related hypothyroidism",
                    "criterion": "autoimmune-related hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on thyroid-replacement hormone",
                    "criterion": "thyroid-replacement hormone therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment",
                    "criterion": "symptomatic lesions amenable to palliative radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should be recovered from the effects of radiation",
                    "criterion": "recovery from effects of radiation",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "o Prior anti-PD1 or anti-CTLA4 therapy is allowed in the dose escalation cohort and prior PD1/PDL1 inhibitors are allowed in the MSI-H expansion cohort.",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-PD1 or anti-CTLA4 therapy is allowed in the dose escalation cohort",
                    "criterion": "prior anti-PD1 or anti-CTLA4 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "dose escalation"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior PD1/PDL1 inhibitors are allowed in the MSI-H expansion cohort",
                    "criterion": "prior PD1/PDL1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cohort",
                            "expected_value": "MSI-H expansion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or symptomatic hypercalcemia",
                    "criterion": "hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ionized calcium > 1.5 mmol/L",
                    "criterion": "ionized calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calcium > 12 mg/dL",
                    "criterion": "serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "corrected serum calcium > ULN",
                    "criterion": "corrected serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection except following situation: Patients with a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection are allowed to be included if: participant on a stable dose of antiviral therapy, HBV viral load below the limit of quantification. HCV viral load below the limit of quantification.",
            "criterions": [
                {
                    "exact_snippets": "known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBsAg status",
                            "expected_value": "reactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection",
                    "criterion": "Hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HCV RNA [qualitative]",
                            "expected_value": "detected"
                        }
                    ]
                },
                {
                    "exact_snippets": "participant on a stable dose of antiviral therapy",
                    "criterion": "antiviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "stable dose",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HBV viral load below the limit of quantification",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "limit of quantification"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HCV viral load below the limit of quantification",
                    "criterion": "HCV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "limit of quantification"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment",
                    "criterion": "major surgical procedure (other than for diagnosis)",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to study treatment initiation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "occurrence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for a major surgical procedure during the study",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "anticipated occurrence during study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis for a more comprehensive list of autoimmune diseases and immune deficiencies), with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Active or history of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Active or history of ... immune deficiency",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "history"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis",
                    "criterion": "specific autoimmune diseases and immune deficiencies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "myasthenia gravis",
                                "myositis",
                                "autoimmune hepatitis",
                                "systemic lupus erythematosus",
                                "rheumatoid arthritis",
                                "inflammatory bowel disease",
                                "antiphospholipid antibody syndrome",
                                "Wegener granulomatosis",
                                "Sjögren syndrome",
                                "Guillain-Barré syndrome",
                                "multiple sclerosis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia",
            "criterions": [
                {
                    "exact_snippets": "Severe infection within 4 weeks prior to initiation of study treatment",
                    "criterion": "severe infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hospitalization for complications of infection",
                    "criterion": "hospitalization for complications of infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bacteremia",
                    "criterion": "bacteremia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "severe pneumonia",
                    "criterion": "severe pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment",
                    "criterion": "systemic immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for systemic immunosuppressive medication during study treatment",
                    "criterion": "anticipated need for systemic immunosuppressive medication",
                    "requirements": [
                        {
                            "requirement_type": "anticipated use during study treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of concurrent second primary malignancy other than the primary cancer within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer",
            "criterions": [
                {
                    "exact_snippets": "History of concurrent second primary malignancy other than the primary cancer within 3 years prior to screening",
                    "criterion": "concurrent second primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "concurrence with primary cancer",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer",
                    "criterion": "second primary malignancy risk",
                    "requirements": [
                        {
                            "requirement_type": "risk of metastasis or death",
                            "expected_value": "negligible"
                        },
                        {
                            "requirement_type": "5-year OS rate",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "malignancy type",
                            "expected_value": [
                                "adequately treated carcinoma in situ of the cervix",
                                "non-melanoma skin carcinoma",
                                "localized prostate cancer",
                                "ductal carcinoma in situ",
                                "Stage I uterine cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina",
            "criterions": [
                {
                    "exact_snippets": "Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment",
                    "criterion": "significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class II or greater cardiac disease",
                    "criterion": "New York Heart Association cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history within 3 months",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "history within 3 months",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
            "criterions": [
                {
                    "exact_snippets": "Any other disease ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "other disease",
                    "requirements": [
                        {
                            "requirement_type": "absence of contraindication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of interference with interpretation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of high risk from treatment complications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic dysfunction ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "metabolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "absence of contraindication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of interference with interpretation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of high risk from treatment complications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "physical examination finding",
                    "requirements": [
                        {
                            "requirement_type": "absence of contraindication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of interference with interpretation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of high risk from treatment complications",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding ... that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications",
                    "criterion": "clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "absence of contraindication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of interference with interpretation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "absence of high risk from treatment complications",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment",
                    "criterion": "treatment with therapeutic oral or IV antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* ANC ≥ 1.5 × 109/L (1500/L) without granulocyte colony-stimulating factor support",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥ 1.5 × 10^9/L (1500/L) without granulocyte colony-stimulating factor support",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        },
                        {
                            "requirement_type": "granulocyte colony-stimulating factor support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 100 × 109/L (100,000/L) without transfusion",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100 × 10^9/L (100,000/L) without transfusion",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        },
                        {
                            "requirement_type": "transfusion support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "* Patients who meet any of the following criteria will be excluded from study entry:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}